Novome gets $43.5M boost for its engineered microbiome therapies
MedCity News
SEPTEMBER 13, 2022
Novome Biotechnologies — a biotech that CEO Blake Wise says is only company to pursue engineered cell therapy with microbes for the treatment of chronic diseases — raised $43.5 million in Series B funds.
Let's personalize your content